PortalPublikationenBasic Susceptibility of Patients with Psoriasis under System...

Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest

Standard

Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest. / Stephan, Brigitte; Rustenbach, Stephan Jeff; Ben-Anaya, Nesrine; Augustin, Matthias; Boehncke, Wolf-Henning; Hertl, Michael; Mrowietz, Ulrich; Staubach-Renz, Petra; Thaçi, Diamant; von Kiedrowski, Ralph; Sorbe, Christina.

in: J CLIN MED, Jahrgang 13, Nr. 13, 26.06.2024, S. 3713.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stephan, B, Rustenbach, SJ, Ben-Anaya, N, Augustin, M, Boehncke, W-H, Hertl, M, Mrowietz, U, Staubach-Renz, P, Thaçi, D, von Kiedrowski, R & Sorbe, C 2024, 'Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest', J CLIN MED, Jg. 13, Nr. 13, S. 3713. https://doi.org/10.3390/jcm13133713

APA

Stephan, B., Rustenbach, S. J., Ben-Anaya, N., Augustin, M., Boehncke, W-H., Hertl, M., Mrowietz, U., Staubach-Renz, P., Thaçi, D., von Kiedrowski, R., & Sorbe, C. (2024). Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest. J CLIN MED, 13(13), 3713. https://doi.org/10.3390/jcm13133713

Vancouver

Stephan B, Rustenbach SJ, Ben-Anaya N, Augustin M, Boehncke W-H, Hertl M et al. Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest. J CLIN MED. 2024 Jun 26;13(13):3713. https://doi.org/10.3390/jcm13133713

Bibtex

@article{fccc0966d24e4939b3ab48f820faa2ad,
title = "Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest",
abstract = "Background: Patients with psoriasis under systemic treatments are in focus regarding their susceptibility to respiratory infections. To analyse real-world data for respiratory infections in patients with psoriasis under systemic treatments. Methods: We analysed data of the prospective, non-interventional German Psoriasis Registry PsoBest and compared rates for respiratory infections of 13,823 patients on systemic treatments for psoriasis and/or psoriatic arthritis in different therapy cohorts before the COVID-19 pandemic. Results: In total, 1415 respiratory infections were observed in 970 patients. Significant differences were observed between biologics and non-biologics, but not within these groups. The highest event rates (events/100 patient years) were identified for TNF-α inhibitors, 8.1, (CI 7.4-8.9), followed by 7.0 for IL-17 inhibitors (6.2-7.9), 5.7 for IL-12/23 and IL-23 inhibitors (5.1-6.5), 4.8 for methotrexate (4.3-5.4), 3.7 for small molecules (3.3-4.2), and 2.7 for retinoids (1.2-5.1). Conclusions: Overall, the susceptibility for respiratory infections in patients under systemic therapy for psoriasis is low compared to published study data and is sufficient as comparative data for COVID-19 studies.",
author = "Brigitte Stephan and Rustenbach, {Stephan Jeff} and Nesrine Ben-Anaya and Matthias Augustin and Wolf-Henning Boehncke and Michael Hertl and Ulrich Mrowietz and Petra Staubach-Renz and Diamant Tha{\c c}i and {von Kiedrowski}, Ralph and Christina Sorbe",
year = "2024",
month = jun,
day = "26",
doi = "10.3390/jcm13133713",
language = "English",
volume = "13",
pages = "3713",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "13",

}

RIS

TY - JOUR

T1 - Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest

AU - Stephan, Brigitte

AU - Rustenbach, Stephan Jeff

AU - Ben-Anaya, Nesrine

AU - Augustin, Matthias

AU - Boehncke, Wolf-Henning

AU - Hertl, Michael

AU - Mrowietz, Ulrich

AU - Staubach-Renz, Petra

AU - Thaçi, Diamant

AU - von Kiedrowski, Ralph

AU - Sorbe, Christina

PY - 2024/6/26

Y1 - 2024/6/26

N2 - Background: Patients with psoriasis under systemic treatments are in focus regarding their susceptibility to respiratory infections. To analyse real-world data for respiratory infections in patients with psoriasis under systemic treatments. Methods: We analysed data of the prospective, non-interventional German Psoriasis Registry PsoBest and compared rates for respiratory infections of 13,823 patients on systemic treatments for psoriasis and/or psoriatic arthritis in different therapy cohorts before the COVID-19 pandemic. Results: In total, 1415 respiratory infections were observed in 970 patients. Significant differences were observed between biologics and non-biologics, but not within these groups. The highest event rates (events/100 patient years) were identified for TNF-α inhibitors, 8.1, (CI 7.4-8.9), followed by 7.0 for IL-17 inhibitors (6.2-7.9), 5.7 for IL-12/23 and IL-23 inhibitors (5.1-6.5), 4.8 for methotrexate (4.3-5.4), 3.7 for small molecules (3.3-4.2), and 2.7 for retinoids (1.2-5.1). Conclusions: Overall, the susceptibility for respiratory infections in patients under systemic therapy for psoriasis is low compared to published study data and is sufficient as comparative data for COVID-19 studies.

AB - Background: Patients with psoriasis under systemic treatments are in focus regarding their susceptibility to respiratory infections. To analyse real-world data for respiratory infections in patients with psoriasis under systemic treatments. Methods: We analysed data of the prospective, non-interventional German Psoriasis Registry PsoBest and compared rates for respiratory infections of 13,823 patients on systemic treatments for psoriasis and/or psoriatic arthritis in different therapy cohorts before the COVID-19 pandemic. Results: In total, 1415 respiratory infections were observed in 970 patients. Significant differences were observed between biologics and non-biologics, but not within these groups. The highest event rates (events/100 patient years) were identified for TNF-α inhibitors, 8.1, (CI 7.4-8.9), followed by 7.0 for IL-17 inhibitors (6.2-7.9), 5.7 for IL-12/23 and IL-23 inhibitors (5.1-6.5), 4.8 for methotrexate (4.3-5.4), 3.7 for small molecules (3.3-4.2), and 2.7 for retinoids (1.2-5.1). Conclusions: Overall, the susceptibility for respiratory infections in patients under systemic therapy for psoriasis is low compared to published study data and is sufficient as comparative data for COVID-19 studies.

U2 - 10.3390/jcm13133713

DO - 10.3390/jcm13133713

M3 - SCORING: Journal article

C2 - 38999279

VL - 13

SP - 3713

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 13

ER -